A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.